GenMark Diagnostics, Inc.
May 2, 2017
PDF

GenMark Diagnostics Reports First Quarter 2017 Results

 

First Quarter Revenue Increased 13% Versus Prior Year to $12.5 million

Over 70 ePlex® Customer Agreements in Place Totaling More than 100 Analyzers

ePlex Blood Culture Identification Fungal Pathogen Panel CE Mark Achieved

 

CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the first quarter ended March 31, 2017.

Revenue for the first quarter of 2017 was $12.5 million, an increase of 13% over the prior year period. Annuity per XT-8 analyzer was $72 thousand in the first quarter and in the mid-$70 thousand range over the last 4 quarters.

Gross profit for the first quarter was $6.2 million, or 49% of revenue, compared with $6.7 million, or 60% of revenue in the same period of 2016.

"Customer experience with ePlex has confirmed its superior ease of use and workflow efficiency, compared with other systems on the market. We designed ePlex to seamlessly integrate the entire diagnostic process from test order entry to reporting patient results," said Hany Massarany, President and Chief Executive Officer of GenMark. "Customers are also very positive about our efforts to expand the ePlex menu, including our three panel approach to sepsis testing. We recently achieved CE Mark for the Blood Culture ID Fungal Pathogen Panel and expect the Gram Positive and Gram Negative Pathogen Panels to follow suit this quarter. Additionally, our Regulatory and Clinical Affairs teams have been working very closely with the FDA on our 510(k) submissions for the ePlex instrument and RP Panel. We have closed out all the questions raised by the agency during its review process and expect FDA clearance soon," added Massarany.

Operating expenses for the first quarter of 2017 were $19.7 million compared to $19.4 million in the same period for 2016. The increase was mainly driven by Marketing and Sales expenses as the Company continues to expand its commercial organization in support of the global ePlex product launch.

Loss per share was $0.30 per share for the first quarter of 2017, which was equal to the loss per share in the first quarter of 2016.

The Company ended the quarter with $24.2 million in cash and cash equivalents. The Company's existing debt facility can provide up to an additional $20 million to support the launch of ePlex internationally as well as domestically.

Business Outlook

For full year 2017, the Company continues to expect revenue in the range of $65 to $70 million and gross margin in the range of 48-52%.

The Company will be hosting a conference call to discuss first quarter results in further detail on Tuesday, May 2, 2017 starting at 4:30 p.m. Eastern Time. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 51141106 approximately five minutes prior to the start time.

ABOUT GENMARK DIAGNOSTICS

GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. The eSensor detection technology is also incorporated into GenMark's sample-to-answer system, ePlex®. For more information, visit www.genmarkdx.com.

SAFE HARBOR STATEMENT

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding our future financial performance, the timely commercialization and regulatory clearance of our ePlex system, and the availability of future financing, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, our ability to successfully commercialize our ePlex system and its related test menu in a timely manner, constraints or inefficiencies caused by unanticipated acceleration and deceleration of customer demand, our ability to successfully expand sales of our product offerings outside the United States, and third-party payor reimbursement to our customers, as well as other risks and uncertainties described under the "Risk Factors" in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

         
GENMARK DIAGNOSTICS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
         
    March 31,
2017
  December 31,
2016
Current assets        
Cash and cash equivalents   $ 13,178     $ 15,959  
Marketable securities   11,007     25,607  
Accounts receivable, net of allowances of $2,749 and $2,740, respectively   7,487     9,048  
Inventories   9,019     6,633  
Prepaid expenses and other current assets   1,419     1,202  
Total current assets   42,110     58,449  
Non-current assets        
Property and equipment, net   18,482     18,268  
Intangible assets, net   2,546     2,670  
Restricted cash   758     758  
Other long-term assets   179     179  
Total assets   $ 64,075     $ 80,324  
Current liabilities        
Accounts payable   $ 5,696     $ 8,703  
Accrued compensation   4,510     5,650  
Loan payable   7,685     7,935  
Other current liabilities   3,159     4,133  
Total current liabilities   21,050     26,421  
Long-term liabilities        
Deferred rent   3,524     3,652  
Long-term debt   12,261     11,880  
Other non-current liabilities   186     220  
Total liabilities   37,021     42,173  
Stockholders' equity        
Preferred stock, $0.0001 par value; 5,000 authorized, none issued        
Common stock, $0.0001 par value; 100,000 authorized; 47,084 and 46,554 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively   5     4  
Additional paid-in capital   396,217     393,322  
Accumulated deficit   (369,188 )   (355,270 )
Accumulated other comprehensive income   20     95  
Total stockholders' equity   27,054     38,151  
Total liabilities and stockholders' equity   $ 64,075     $ 80,324  
                 
                 
GENMARK DIAGNOSTICS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands, except per share data)
     
    Three Months Ended
    March 31,
    2017   2016
Revenue        
Product revenue   $ 12,470     $ 10,959  
License and other revenue   65     105  
Total revenue   12,535     11,064  
Cost of revenue   6,352     4,375  
Gross profit   6,183     6,689  
Operating expenses        
Sales and marketing   4,693     3,709  
General and administrative   4,011     3,419  
Research and development   11,035     12,269  
Total operating expenses   19,739     19,397  
Loss from operations   (13,556 )   (12,708 )
Other income (expense)        
Interest income   52     29  
Interest expense   (507 )   (277 )
Other income   95     33  
Total other expense   (360 )   (215 )
Loss before provision for income taxes   (13,916 )   (12,923 )
Income tax expense   1     35  
Net loss   $ (13,917 )   $ (12,958 )
Net loss per share, basic and diluted   $ (0.30 )   $ (0.30 )
Weighted average number of shares outstanding, basic and diluted   46,846   42,672
Other comprehensive loss        
Net loss   $ (13,917 )   $ (12,958 )
Foreign currency translation adjustments   91     47  
Net unrealized losses on marketable securities, net of tax   (16 )   (17 )
Comprehensive loss   $ (13,842 )   $ (12,928 )
                 
                 
GENMARK DIAGNOSTICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
     
    Three Months Ended March 31,
    2017   2016
Operating activities        
Net loss   $ (13,917 )   $ (12,958 )
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization   1,217     900  
Amortization of premiums on investments   19     16  
Amortization of deferred debt issuance costs   151     92  
Stock-based compensation   2,808     2,402  
Provision for bad debt   9     29  
Non-cash inventory adjustments   317     75  
Other non-cash adjustments   (85 )   (49 )
Changes in operating assets and liabilities:        
Accounts receivable   1,558     1,385  
Inventories   (3,118 )   501  
Prepaid expenses and other assets   (216 )    
Accounts payable   (2,821 )   617  
Accrued compensation   (1,144 )   989  
Other liabilities   (343 )   (42 )
Net cash used in operating activities   (15,565 )   (6,043 )
Investing activities        
Payments for intellectual property licenses       (800 )
Purchases of property and equipment   (1,888 )   (966 )
Proceeds from sale of marketable securities   13,896      
Maturities of marketable securities   700     (1,766 )
Net cash provided by (used in) investing activities   12,708     (966 )
Financing activities        
Principal repayment of borrowings   (6 )   (5 )
Proceeds from borrowings        
Costs associated with debt issuance   (20 )   (10 )
Proceeds from stock option exercises   88     345  
Net cash provided by financing activities   62     330  
Effect of exchange rate changes on cash   14     7  
Net decrease in cash and cash equivalents   (2,781 )   (7,472 )
Cash and cash equivalents at beginning of period   15,959     35,385  
Cash and cash equivalents at end of period   $ 13,178     $ 27,913  
Non-cash investing and financing activities        
Transfer of instruments from (to) property and equipment into inventory   $ (415 )   $ 38  
Property and equipment costs included in accounts payable   $ 183     $ 285  
Supplemental cash flow disclosures        
Cash paid for income taxes, net   $ 5     $ 13  
Cash received for interest   $ 108     $ 21  
Cash paid for interest   $ 347     $ 184  

 

GenMark Diagnostics, Inc.
Hany Massarany, President/Chief Executive Officer
760-448-4325

Source: GenMark Diagnostics, Inc.

 

 

News Provided by Acquire Media